• HIV-1 Nuclear Pore Remodeling Licences Infection

  2026-09-04

  The reference study identifies nuclear import through the nuclear pore complex as a major barrier to HIV-1 infection of resting CD4+ T cells. It shows that cell–cell spread activates a CD4–LCK–CDK1 pathway that remodels nucleoporins and enables capsid nuclear import without requiring conventional cell-cycle entry.

• ARID1A-Dependent Melanoma Drug Resistance

  2026-09-03

  The reference study integrates signaling, transcriptional, proteomic, and network-level data to explain how ARID1A loss reshapes early responses to BRAF/MAPK inhibition in melanoma. Its identification of PRKD1, JUN, and NCK1 as resistance-associated nodes provides a practical framework for designing genotype-aware assays that measure adaptive signaling rather than relying only on endpoint proliferation.

• Tomivosertib: MNK1 Inhibitor Workflow for AML

  2026-09-03

  Tomivosertib provides a selective way to connect MNK1/2 activity with eIF4E phosphorylation, AML cell survival, and progenitor growth. This practical guide translates the reference study into reproducible assay design, combination testing, orthogonal validation, and troubleshooting strategies.

• PD98059 for MEK Pathway Experiments

  2026-09-02

  PD98059 is a reversible MEK inhibitor for resolving ERK-dependent changes in proliferation, apoptosis, and oxidative-stress responses. This practical guide connects pathway validation in cultured cells with the ERK–mitochondrial apoptosis workflow used in a cyclophosphamide-induced liver injury study.

• ARID1A-Dependent Resistance in Melanoma Multi-Omics

  2026-09-02

  The reference study integrates multi-omics measurements to show how ARID1A loss rewires signaling, transcription, and immune-related protein programs during BRAF/MAPK inhibitor response. Its identification of PRKD1, JUN, and NCK1 as resistance-associated network nodes provides a mechanistic framework for studying adaptive resistance beyond simple MAPK pathway reactivation.

• LDN-193189 Workflow for BMP Signaling Studies

  2026-09-01

  LDN-193189 enables branch-selective interrogation of ALK2/ALK3-driven BMP signaling, from rapid Smad readouts to epithelial barrier and cell-plasticity assays. This workflow connects mechanistic phosphoprotein measurements with practical endpoints relevant to heterotopic ossification research, mammary biology, and epithelial homeostasis.

• Gastrodin, AT1 Signaling, and Reactive Astrocytes

  2026-09-01

  The reference study identifies a microglia-to-astrocyte signaling framework in which inflammatory conditioned medium alters astrocytic renin–angiotensin system components, SIRT3, phenotype markers, cytokines, and neurotrophic factors. By using azilsartan to perturb AT1 signaling, the work connects gastrodin’s effects with RAS-dependent astrocyte responses while also highlighting the limitations of simple A1/A2 marker classification.

• Elobixibat hydrate: IBAT Research Workflows

  2026-08-31

  Build reproducible gastrointestinal and metabolic assays around Elobixibat hydrate, from transporter blockade through bile acid, GLP-1, motility, and metabolic readouts. Practical handling guidance, assay controls, and troubleshooting help distinguish true IBAT biology from vehicle, precipitation, and tissue-viability artifacts.

• Tomivosertib Workflows for MNK1–eIF4E Studies

  2026-08-31

  Tomivosertib enables direct interrogation of MNK1/2-dependent eIF4E phosphorylation across metabolic, cancer, and neuronal models. This workflow-focused guide connects dose selection and pathway validation with translatome-aware assays and practical troubleshooting.

• RRP Restores Lipid Metabolism in Hepatic IRI

  2026-08-30

  The reference study shows that Radix Rehmanniae Praeparata extracts reduce hepatic ischemia-reperfusion injury by correcting hepatocyte cholesterol handling, not only by providing nonspecific cytoprotection. Its mechanistic model connects AMPK activation and mTOR inhibition with suppression of SCAP-SREBP2 cholesterol synthesis and enhancement of LXRα-dependent cholesterol efflux.

• PP 1: Src Family Tyrosine Kinase Inhibitor

  2026-08-29

  PP 1 is a selective Src family tyrosine kinase inhibitor with nanomolar activity against Lck and Fyn. Its research applications include inhibition of Src-family kinases in cancer research, T cell activation modulation, and RET oncogene inhibition, while its assay and model-specific limits require careful controls.

• M344 in Neuroblastoma: Mechanisms and Tumor Control

  2026-08-28

  The 2025 study by Brumfield and colleagues shows that M344 increases histone acetylation, suppresses malignant neuroblastoma phenotypes, and enhances tumor control in vivo. Its comparative and combination-treatment experiments position M344 as a useful preclinical model for studying HDAC inhibition, tolerability, and post-therapy tumor rebound.

• Vemurafenib (PLX4032) in Melanoma Research

  2026-08-28

  Vemurafenib, also called PLX4032 and RG7204, is a selective BRAF kinase inhibitor used to study BRAF-mutant melanoma biology. Its research value includes melanoma cell proliferation inhibition, pathway-response profiling, xenograft studies, and analysis of adaptive resistance.

• Gramine Workflow for TNBC Ferroptosis Research

  2026-08-27

  Gramine supports a mechanism-led workflow for studying ferroptosis in triple-negative breast cancer, linking cell viability, lipid oxidation, and the CUL3–MTDH axis. This guide translates the reference findings into practical dosing, validation, and troubleshooting choices for reproducible cancer biology research.

• Nigericin Sodium Salt: Practical Lab Guide

  2026-08-27

  Nigericin sodium salt is a potassium ionophore for experimentally controlled ion transport across biological membranes, cytoplasmic pH regulation, and ionic-environment studies such as platelet aggregation modulation. This guide covers dossier-supported handling and workflow controls, while noting that the compound is for research use only and should not be treated as a diagnostic or therapeutic reagent.

8453 records 1/564 page Next 12345 下5页 Last page